New Zealand Regulatory Impact Statement
September 2003
In November 2002 Cabinet [CAB Min (02) 31/9 refers] agreed that complementary medicines should be regulated as therapeutic products under a risk-based regulatory scheme, and agreed in principle that they should be regulated by the joint therapeutic products agency. Officials were directed to report back to Cabinet on the outcome of further work to refine the details of the regulatory scheme and investigate options for distributing regulatory costs across the sector in a way that is equitable, and which reduces the potential cost burden on smaller distributors of complementary medicines.
Contents of this document
- Background
- Statement of the nature of the problem and the need for government action
- Statement of the public policy objectives
- Health objectives
- Wider objectives
- Statement of feasible options (regulatory and/or non-regulatory) that may constitute viable means for achieving the desired objectives
- Option 1: Status quo
- Option 2: Flat rate levy based on turnover
- Option 3: A cost recovery schedule based on fees and charges (preferred option)
- Statement of the net benefits of the proposal, including the total regulatory costs (administrative, compliance and economic costs) and benefits (including non-quantifiable benefits) of the proposal, and other feasible options
- Government
- Complementary medicines industry
- Consumers
- Wider economy
- Statement of consultation undertaken
- Business compliance cost statement